Devin B. Lowe

Anti-idiotype responses abrogate anti-CD4-induced tolerance to a tumor-specific antigen and promote systemic tumor immunity.

In vitro simian virus 40 large tumor antigen expression correlates with differential immune responses following DNA immunization.

DNA vaccines: successes and limitations in cancer and infectious disease.

Fc gamma receptors play a dominant role in protective tumor immunity against a virus-encoded tumor-specific antigen in a murine model of experimental pulmonary metastases.

A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17.

Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase.

Role of the innate immune response and tumor immunity associated with simian virus 40 large tumor antigen.

Vaccines and immunotherapeutics for the treatment of malignant disease.

Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens.

CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA.

Chronic inflammation and immunologic-based constraints in malignant disease.

Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo.

Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice.

Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.

The role of gamma interferon in DNA vaccine-induced tumor immunity targeting simian virus 40 large tumor antigen.

Shock block for improved immunotherapy.

Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma.

Monitoring antigen-specific T cell responses using real-time PCR.